Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

FDA Panel Unanimously Recommends New DNA Stool Test

March 27th 2014

The FDA's Molecular and Clinical Genetics advisory committee has unanimously supported the safety, efficacy, and positive risk-benefit profile of the noninvasive stool-based DNA test Cologuard in a 10-0 vote.

FDA Panel Narrowly Supports New CRC Blood Test

March 27th 2014

The blood-based colorectal cancer (CRC) screening test Epi proColon passed the scrutiny of the FDA's Molecular and Clinical Genetics advisory panel in a close 5-4 vote with 1 abstention in support of the claim that the test's benefits outweigh its risks

G-202 Represents Novel Approach for Attacking Advanced HCC

March 24th 2014

Prodrug chemotherapy is an exciting approach by which higher concentrations of cytotoxic or biologically active agents can be achieved at a tumor site while avoiding the systemic toxicity of a non-cell-specific toxin.

Dr. Bordonaro on the Treatment of Advanced CRC

March 13th 2014

Roberto Bordonaro, MD, chair, medical oncology, Garibaldi Hospital, Catania, Italy, discusses treatment options for patients with colorectal cancer who fail on oxaliplatin- and irinotecan-based chemotherapy.

Dr. Peeters on the Future of Colorectal Cancer

March 11th 2014

Marc Peeters, MD, PhD, department of oncology, Antwerp University Hospital, Antwerpen, Belgium, discusses the future of the treatment of colorectal cancer.

Dr. Fine on GTX in Inoperable Pancreatic Cancer

March 5th 2014

Robert L. Fine, MD, an associate professor of Medicine at New York Presbyterian Hospital-Columbia University Medical Center, discusses a phase II study that evaluated the efficacy of neoadjuvant gemcitabine, docetaxel, and capecitabine (GTX) in patients with inoperable pancreatic adenocarcinoma

Conclusion: Effective Sequencing of Treatments for pNETs

February 28th 2014

Treatment Sequencing and Combinations in pNETs

February 28th 2014

Case Study: Treating Metastatic Pancreatic NETs

February 28th 2014

Utilizing Everolimus and Sunitinib in pNETs

February 28th 2014

RADIANT-3 Trial: Everolimus for Patients With pNETs

February 28th 2014

Everolimus in Pancreatic Neuroendocrine Tumors

February 28th 2014

Role of Somatostatin Analogs for Patients With pNETs

February 28th 2014

Alkylating Agents in Pancreatic Neuroendocrine Tumors

February 28th 2014

Treatment of Neuroendocrine Tumor Liver Metastases

February 28th 2014

Pathologic Classification of Neuroendocrine Tumors

February 28th 2014

Pancreatic Neuroendocrine Tumor Diagnosis Challenges

February 28th 2014

Integrating Genetic Counseling Into an Oncology Practice Can Benefit High-Risk Families

February 26th 2014

Genetic counseling-including testing and risk assessment-is one of the most rapidly growing areas of oncology and has become the standard of care for patients with a personal and family history of breast, ovary, or colon cancer.

Final Thoughts on the Treatment of mCRC

February 26th 2014

Panitumumab, Regorafenib, and Ziv-aflibercept in mCRC

February 26th 2014